Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Last Updated: October 29, 2015; Last Reviewed: October 29, 2015
Initiaiting Primary Prophylaxis
|Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials in children† with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children† from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children† with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children† from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion
†Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents
The major mode of transmission of Toxoplasma gondii infection to infants and young children is congenital, occurring almost exclusively in neonates born to women who sustain primary Toxoplasma infection during pregnancy. The estimated incidence of congenital toxoplasmosis in the United States is one case per 1,000 to 12,000 live-born infants.1,2 The seroprevalence of T. gondii in U.S.-born individuals aged 12 to 49 years declined from 14.1% in the National Health and Nutrition Examination Survey from 1988 to 1994 to 9.0% from 1999 to 2004.3 Older children, adolescents, and adults typically acquire Toxoplasma infection by eating undercooked meat that contains parasitic cysts or by unintentionally ingesting sporulated oocysts from cat feces in soil or contaminated food or water.4 In the United States, eating raw shellfish including oysters, clams, and mussels was recently identified as a novel risk factor for acute infection.5 Cats are the only definitive host for T. gondii. However, cats excrete oocysts in their feces only transiently after initial infection, and most studies have failed to show a correlation between cat ownership and Toxoplasma infection in humans. Indeed, Toxoplasma infection in humans in the United States has declined despite increased cat ownership.4
The overall risk of maternal-fetal transmission in HIV-uninfected women who acquire primary Toxoplasma infection during pregnancy is 29% (95% confidence interval [CI], 25%–33%), with variation depending upon the trimester during which primary maternal infection occurs.6 The risk of congenital infection is low among infants born to women who become infected during the first trimester (range: 2%–6%) but increases sharply thereafter, with a risk as high as 81% in women who become infected during the last few weeks of pregnancy.6,7 Infection of the fetus in early gestation usually results in more severe disease than does infection late in gestation.
The prevalence of latent Toxoplasma infection in HIV-infected and HIV–uninfected women in the United States was assessed in a cross-sectional study of 2,525 non-pregnant women enrolled in the Women’s Interagency Health Study.8 The prevalence of Toxoplasma seropositivity was 15% and did not differ by HIV infection status. The overall rate of mother-to-child transmission (MTCT) of Toxoplasma in HIV-infected pregnant women is unknown; however, a few cases of MTCT of Toxoplasma in HIV-infected women have been reported.9-13 HIV-infected women may be at increased risk of transmitting T. gondii to their fetuses, and serologic testing for Toxoplasma should be performed on all HIV-infected pregnant women. Prenatal transmission of T. gondii is rare from women without HIV infection who acquired chronic Toxoplasma infection before pregnancy.14 However, with HIV coinfection, perinatal transmission of Toxoplasma has been observed in women with chronic Toxoplasma infection (transmission rate: <4%), presumably because of reactivation of replication of the organism in women who are severely immunosuppressed.9-12
Central nervous system (CNS) infection with T. gondii was reported as an AIDS-indicator condition in <1% of pediatric AIDS cases before the advent of combination antiretroviral therapy (cART).15 Since then, this condition is rarely encountered in HIV-infected U.S. children. CNS toxoplasmosis occurred in 5 of 2,767 (0.2%) HIV-infected children enrolled in the long-term follow-up study Pediatric AIDS Clinical Trials Group 219c since cART has been available.16 Infection is considered to have occurred in utero in most cases of Toxoplasma encephalitis (TE) seen in HIV-infected children.
More rarely, it has been reported in older HIV-infected children, who presumably had primary acquired toxoplasmosis.17-19 As in adults, the greatest risk is among severely immunosuppressed children (i.e., CD4 T lymphocyte [CD4] cell count <50 cells/mm3).
In studies of non-immunocompromised infants with congenital toxoplasmosis, most infants (70%–90%) are asymptomatic at birth. However, most asymptomatic children develop late sequelae (i.e., retinitis, visual impairment, and intellectual or neurologic impairment), with onset of symptoms ranging from several months to years after birth. Symptoms in newborns take either of two presentations: generalized disease or predominantly neurologic disease. Symptoms can include maculopapular rash; generalized lymphadenopathy; hepatosplenomegaly; jaundice; hematologic abnormalities including anemia, thrombocytopenia, and neutropenia; and substantial CNS disease including hydrocephalus, intracerebral calcification, microcephaly, chorioretinitis, and seizures.20
Toxoplasmosis acquired after birth most often is initially asymptomatic. When symptoms occur, they are frequently nonspecific and can include malaise, fever, sore throat, myalgia, lymphadenopathy (cervical), and a mononucleosis-like syndrome featuring a maculopapular rash and hepatosplenomegaly.21
TE should be considered in all HIV-infected children with new neurologic findings, but especially those with severe immunosuppression. Although focal findings are typical, the initial presentation can vary and reflect diffuse CNS disease. Generalized symptoms include fever, reduced alertness, and seizures.
Isolated ocular toxoplasmosis is rare in immunocompromised children and usually occurs in association with CNS infection. As a result, a neurologic examination is indicated for children in whom Toxoplasma chorioretinitis is diagnosed. Ocular toxoplasmosis appears as white retinal lesions with little associated hemorrhage; visual loss can occur initially.
Less frequent presentations in HIV-infected children with reactivated chronic toxoplasmosis include systemic toxoplasmosis, pneumonitis, hepatitis, and cardiomyopathy/myocarditis.12,22
All infants whose mothers are both HIV-infected and seropositive for Toxoplasma should be evaluated for congenital toxoplasmosis (AIII).23 Congenital toxoplasmosis can be diagnosed by enzyme-linked immunoassay or an immunosorbent assay to detect Toxoplasma-specific immunoglobulin M (IgM), IgA, or IgE in neonatal serum within the first 6 months of life or persistence of specific immunoglobulin G antibody beyond age 12 months.24-28 IgA may be more sensitive for detecting congenital infection than IgM or IgE.25 However, approximately 20% to 30% of infants with congenital toxoplasmosis will not be identified during the neonatal period with IgA or IgM assays.26
Serologic testing is the major method of diagnosis, but interpretation of assays often is confusing and difficult. When considering a diagnosis of congenital toxoplasmosis, specialized reference laboratories can perform serology, isolation of organisms and polymerase chain reaction (PCR) and can offer assistance in interpreting results.25,28
Additional methods that can be used to diagnose infection in the newborn include isolation of the Toxoplasma parasite by mouse inoculation or inoculation in tissue cultures of cerebrospinal fluid (CSF), urine, placental tissue, amniotic fluid, or infant blood. T. gondii DNA can be detected by PCR performed on clinical specimens (e.g., white blood cells, CSF, amniotic fluid, tissue) in a reference laboratory.25,26 The following evaluation should be undertaken for all newborns in whom a diagnosis of toxoplasmosis is suspected: ophthalmologic, auditory, and neurologic examinations; lumbar puncture; and imaging of the head (either CT or magnetic resonance imaging [MRI] scans) to determine whether hydrocephalus or calcifications are present.
CNS toxoplasmosis is presumptively diagnosed on the basis of clinical symptoms, serologic evidence of infection, and presence of a space-occupying lesion on imaging studies of the brain.29 TE rarely has been reported in individuals without Toxoplasma-specific IgG antibodies; therefore, negative serology does not definitively exclude that diagnosis. Brain computer tomography (CT) that demonstrates multiple, bilateral, ring-enhancing lesions, especially in the basal ganglia and cerebral corticomedullary junction, would be typical of TE. Calcifications are more typical in congenital toxoplasmosis than in TE seen later in life. Magnetic resonance imaging (MRI) is more sensitive and will confirm basal ganglia lesions in most patients.30 F-fluoro-2-deoxyglucose–positive emission tomography reportedly is helpful in adults in distinguishing Toxoplasma abscesses from primary CNS lymphoma, but the accuracy is not high, and this test is not widely available.
Definitive diagnosis of TE requires histologic or cytologic confirmation by brain biopsy, which may demonstrate leptomeningeal inflammation, microglial nodules, gliosis, and Toxoplasma cysts. Brain biopsy is reserved by some experts for patients who do not respond to specific therapy.
All HIV-infected children and adolescents and their caregivers should be counseled about sources of T. gondii infection. They should be advised not to eat raw or undercooked meat, including undercooked lamb, beef, pork, or venison (BIII). All meat (lamb, beef, and pork) should be cooked to an internal temperature of 145°F for 3 minutes.31 However, a study has found that T. gondii can survive at 64°C (147.2°F) for 3 minutes, so higher temperatures than this seem best for immunosuppressed patients.32 Ground meat and wild game meat should be cooked to 71°C (160°F). Poultry should be cooked to 74°C (165°F). Hands should be washed after contact with raw meat and after gardening or other contact with soil; in addition, fruits and vegetables should be washed well before being eaten raw (BIII). Stray cats should not be handled or adopted; a cat already in the household should be kept inside and the litter box changed daily, preferably by an HIV-uninfected individual who is not pregnant (BIII). Cats should be fed only canned or dried commercial food or well-cooked table food, not raw or undercooked meats (BIII). Patients need not be advised to part with their cats or to have their cats tested for toxoplasmosis (AII).
In the United States, routine Toxoplasma serologic screening of HIV-infected children whose mothers do not have toxoplasmosis is not recommended because of its low incidence. However, in regions with high incidence of Toxoplasma infection (≥1% per year), or for children immigrating from such regions, serologic testing can be selectively considered for HIV-infected children aged >12 months (CIII). HIV-infected adolescents without previous Toxoplasma infection should undergo serologic testing (CIII). Toxoplasma-seronegative adults and adolescents who are not taking Pneumocystis pneumonia (PCP) prophylaxis known to be active against TE should be retested for IgG antibody to Toxoplasma if their CD4 cell counts decline to <100 cells/mm3 to determine whether they have seroconverted to Toxoplasma.
Toxoplasma-seropositive adolescents and adults who have CD4 cell counts <100 cells/mm3 should be given prophylaxis against TE.33 Specific levels of immunosuppression that increase the risk of TE in children are less well defined. Toxoplasma-seropositive children with CD4 percentages <15% should be given prophylaxis against TE (AIII). For children aged ≥6 years, the same absolute CD4 count level used for HIV-infected adults can be used (AIII).
In HIV-infected adolescents and adults, the double-strength-tablet daily dose of trimethoprim-sulfamethoxazole (TMP-SMX) recommended as the preferred regimen for PCP prophylaxis is effective TE prophylaxis (AII).33 Data from case series in children and from trials in adults support this as the preferred regimen in children using age-based dosing (See Table: Dosing Recommendations for the Prevention and Treatment of Toxoplasma gondii) (BIII). TMP-SMX, one double-strength tablet 3 times weekly (or 3 consecutive days a week), is an alternative (BIII). If patients cannot tolerate TMP-SMX, the recommended alternative is dapsone-pyrimethamine, which also is effective against PCP (BI*).34,35 Atovaquone with or without pyrimethamine also can be considered (CIII). Single-drug prophylaxis with dapsone, pyrimethamine, azithromycin, or clarithromycin cannot be recommended (AIII). Aerosolized pentamidine does not protect against TE and is not recommended.33,36 Severely immunosuppressed children who are not receiving TMP-SMX or atovaquone who are seropositive for Toxoplasma should be given prophylaxis for both PCP and toxoplasmosis (i.e., dapsone plus pyrimethamine) (BIII).
Discontinuing Primary Prophylaxis
Multiple observational studies37-39 and two randomized trials40,41 have reported that primary prophylaxis can be discontinued with minimal risk of TE in patients who have responded to cART with an increase in CD4 cell count to ≥200 cells/mm3 for >6 months. Although patients with CD4 cell counts of <100 cells/mm3 are at greatest risk of TE, the risk of TE when CD4 cell counts increase to 100 to 200 cells/mm3 has not been studied as rigorously as an increase to >200 cells/mm3. Thus, the recommendation for adults and adolescents specifies discontinuing prophylaxis after an increase to >200 cells/mm3. Discontinuing primary TE prophylaxis when CD4 cell counts have increased to >200 cells/mm3 is recommended because prophylaxis adds limited disease prevention for toxoplasmosis and because discontinuing drugs reduces pill burden, the potential for drug toxicity, drug interactions, selection of drug-resistant pathogens, and cost. Data do not exist on the safety of discontinuing primary TE prophylaxis for HIV-infected children whose immunologic status improves on cART. Data on adults suggest discontinuation of TMP-SMX may be safe once a child responds to cART with a sustained rise in CD4 percentage above 15%; for children aged ≥6 years, the same CD4 cell count used for HIV-infected adults can be used (BIII). A sustained response in children has been defined as a CD4 count or percentage above the threshold level for >3 consecutive months after receiving cART for >6 months.
Prophylaxis should be reintroduced in HIV-infected adults (AIII), adolescents (AIII), and children ≥6 years old (BIII) if the CD4 cell count decreases to <100 to 200 cells/mm3 or the CD4 percentage falls below 15% for HIV-infected children aged <6 years (BIII).
Pregnant women with suspected or confirmed primary toxoplasmosis and newborns with possible or documented congenital toxoplasmosis should be managed in consultation with an appropriate infectious disease specialist. Although controversy exists about the efficacy of treating pregnant women who have acute toxoplasmosis in an attempt to prevent infection of the fetus,42 most experts would recommend such therapy (BII).23 Empiric therapy should be strongly considered for newborns of HIV-infected mothers who had symptomatic or asymptomatic primary Toxoplasma infection during pregnancy, regardless of whether treatment was administered during pregnancy (BIII).
The preferred treatment for congenital toxoplasmosis is pyrimethamine combined with sulfadiazine, with supplementary leucovorin (folinic acid) to minimize pyrimethamine-associated hematologic toxicity (AII).20,43 The preferred treatment for acquired toxoplasmosis in HIV-infected children is sulfadiazine plus pyrimethamine and leucovorin (AI*). Please refer to http://www.daraprimdirect.com for information regarding access to pyrimethamine. If pyrimethamine is unavailable, clinicians may substitute age-appropriate-dosed trimethoprim-sulfamethoxazole in place of the combination of sulfadiazine, pyrimethamine, and leucovorin. Although the optimal duration of therapy is undefined, the recommended duration of treatment for congenital toxoplasmosis in HIV-uninfected infants is 12 months (AII).43 Older HIV-infected children with acquired CNS, ocular, or systemic toxoplasmosis should be treated with pyrimethamine and leucovorin plus sulfadiazine (AI*). Acute therapy should be continued for 6 weeks, assuming clinical and radiologic improvement (BII*). Longer courses of treatment may be required for extensive disease or poor response after 6 weeks. The primary alternative for sulfadiazine in patients who develop sulfonamide hypersensitivity is clindamycin, administered with pyrimethamine and leucovorin (AI*). Azithromycin instead of clindamycin also has been used with pyrimethamine and leucovorin in sulfa-allergic adults, but this regimen has not been studied in children. Extrapolation of doses used in adults corresponds to a dose of 20 mg/kg given every 24 hours (maximum 1,000 mg) but this dose has not been evaluated in children.
Another alternative in adults is atovaquone plus pyrimethamine and leucovorin, or atovaquone with sulfadiazine alone, or atovaquone as a single agent in patients intolerant to both pyrimethamine and sulfadiazine; however, these regimens have not been studied in children (BII*). In adults, atovaquone is dosed at twice the total daily dose used for PCP prophylaxis and is divided into four doses per day, but such dosing for treatment of acquired toxoplasmosis in children has not been evaluated. In a small (77 subjects) randomized trial in adults, TMP-SMX was reported to be effective and better tolerated than pyrimethamine-sulfadiazine.44 Others have reported similar efficacy in open-label observational studies.45 However, this has not yet been studied in children.
For isolated ocular toxoplasmosis in immunocompetent hosts, TMP-SMX alone is as effective as pyrimethamine-sulfadiazine.46 However, these data have not been duplicated in HIV-infected patients; therefore, this regimen cannot be recommended for this group of patients.
Based upon treatment of congenital toxoplasmosis in HIV-uninfected children, corticosteroids such as dexamethasone and prednisone are recommended for all HIV-infected children with CNS disease when CSF protein is highly elevated (i.e., >1,000 mg/dL) or who have focal lesions with substantial mass effects (BIII). Because of the potential immunosuppressive effects of steroids, they should be discontinued as soon as possible.
Anticonvulsants should be given to children with TE who have a history of seizures (AIII) but should not be administered prophylactically to children without a history of seizures (BIII). Anticonvulsants, if administered, should be continued at least through acute therapy.
Although the initiation of cART aids in the treatment of many opportunistic infections and malignancies, it has not been definitively shown to improve the outcome of TE therapy.
Monitoring and Adverse Events, Including IRIS
Children with TE should be routinely monitored for clinical and radiologic improvement and for adverse effects of treatment; changes in antibody titers are not useful for monitoring responses to therapy.
Toxoplasmosis-associated immune reconstitution inflammatory syndrome (IRIS) has been described rarely in HIV-infected adults and has not been described in HIV-infected children, although it could presumably occur.47,48 IRIS in HIV-infected pregnant women may pose additional risk to the fetuses49 although any unique risk for pregnant women co-infected with HIV and Toxoplasma has not been defined.
Pyrimethamine can be associated with rash (including Stevens-Johnson syndrome) and nausea. The primary toxicity of pyrimethamine is reversible bone marrow suppression (i.e., neutropenia, anemia, and thrombocytopenia). A complete blood count should be performed at least weekly in children who are on daily pyrimethamine and at least monthly in those on less-than-daily dosing (AIII). Leucovorin (folinic acid) always should be administered with pyrimethamine; increased doses of leucovorin may be required in the event of marrow suppression. Because of the long half-life of pyrimethamine, leucovorin should be continued 1 week after pyrimethamine has been discontinued.
Adverse effects of sulfadiazine include rash, fever, leukopenia, hepatitis, gastrointestinal (GI) symptoms (e.g., nausea, vomiting, diarrhea), and crystalluria. Clindamycin can be associated with fever, rash, and GI symptoms (e.g., nausea; vomiting, and diarrhea, and including pseudomembranous colitis) and hepatotoxicity.
Drug interactions between anticonvulsant and antiretroviral drugs should be evaluated. Patients receiving corticosteroids should be closely monitored for development of other opportunistic infections.
Managing Treatment Failure
Brain biopsy should be considered in the event of early clinical or radiologic neurologic deterioration despite adequate empiric treatment or in children who do not clinically respond to anti-Toxoplasma therapy after 10 to 14 days. In children who undergo brain biopsy and have confirmed histopathologic evidence of TE despite treatment, a switch to an alternative regimen as previously described should be considered (BIII).
Patients who have completed initial therapy for acquired TE should be given suppressive therapy (i.e., secondary prophylaxis or chronic maintenance therapy) (AI*)50,51 until immune reconstitution occurs with cART. The combination of pyrimethamine, sulfadiazine, and leucovorin is highly effective for this purpose (AI*). A commonly used regimen for patients who cannot tolerate sulfa drugs is pyrimethamine plus clindamycin with leucovorin (BI*); however, only the combination of pyrimethamine plus sulfadiazine provides protection against PCP as well. Data on adults indicate atovaquone with or without pyrimethamine also can be considered for children (CIII). Limited data support the use of TMP-SMX for secondary prophylaxis;52 this regimen should be used only for patients who do not tolerate pyrimethamine plus sulfadiazine or pyrimethamine plus clindamycin (CIII) or if pyrimethamine is unavailable.
Discontinuing Secondary Prophylaxis
Adults and adolescents receiving secondary prophylaxis for acquired TE are at low risk of recurrence of TE when they have successfully completed their initial therapy, continue to have no signs or symptoms of TE, and have a sustained increase in CD4 cell count of >200 cells/mm3 after cART (i.e., >6 months).38,39,41,53,54 Discontinuing chronic maintenance therapy in HIV-infected adolescents and adults who meet these criteria is a reasonable consideration. The highest risk of relapse appears to occur within the first 6 months after stopping secondary prophylaxis. Some specialists would obtain an MRI of the brain as part of their evaluation to determine whether discontinuing therapy is appropriate. The safety of discontinuing secondary prophylaxis after immune reconstitution with cART in children has not been studied extensively. However, given the data in adults, clinicians caring for HIV-infected children aged 1 to <6 years can consider discontinuing secondary prophylaxis against T. gondii after they have completed TE therapy and ≥6 months of stable cART and are asymptomatic and once the CD4 percentage has risen to ≥15% for >6 consecutive months (BIII). For children aged ≥6 years, the same CD4 cell count used in adults (CD4 count >200 cells/mm3) also can be used (BIII). Prophylaxis should be re-instituted if these parameters are not met.
- Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med. Jun 30 1994;330(26):1858-1863. Available at http://www.ncbi.nlm.nih.gov/pubmed/7818637.
- Jara M, Hsu HW, Eaton RB, Demaria A, Jr. Epidemiology of congenital toxoplasmosis identified by population-based newborn screening in Massachusetts. Pediatr Infect Dis J. Dec 2001;20(12):1132-1135. Available at http://www.ncbi.nlm.nih.gov/pubmed/11740319.
- Smith KL, Wilson M, Hightower AW, et al. Prevalence of Toxoplasma gondii antibodies in US military recruits in 1989: comparison with data published in 1965. Clin Infect Dis. Nov 1996;23(5):1182-1183. Available at http://www.ncbi.nlm.nih.gov/pubmed/8922828.
- Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol. Aug 15 2001;154(4):357-365. Available at http://www.ncbi.nlm.nih.gov/pubmed/11495859.
- Jones JL, Dargelas V, Roberts J, Press C, Remington JS, Montoya JG. Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis. Sep 15 2009;49(6):878-884. Available at http://www.ncbi.nlm.nih.gov/pubmed/19663709.
- Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. May 29 1999;353(9167):1829-1833. Available at http://www.ncbi.nlm.nih.gov/pubmed/10359407.
- Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis. Feb 15 2002;185 Suppl 1:S73-82. Available at http://www.ncbi.nlm.nih.gov/pubmed/11865443.
- Falusi O, French AL, Seaberg EC, et al. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis. Dec 1 2002;35(11):1414-1417. Available at http://www.ncbi.nlm.nih.gov/pubmed/12439806.
- Minkoff H, Remington JS, Holman S, Ramirez R, Goodwin S, Landesman S. Vertical transmission of toxoplasma by human immunodeficiency virus-infected women. Am J Obstet Gynecol. Mar 1997;176(3):555-559. Available at http://www.ncbi.nlm.nih.gov/pubmed/9077606.
- Dunn D, Newell ML, Gilbert R. Low risk of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. Pediatr Infect Dis J. Jan 1997;16(1):84. Available at http://www.ncbi.nlm.nih.gov/pubmed/9002113.
- Dunn D, Newell ML, Gilbert R. Low incidence of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. European Collaborative Study and Research Network on Congenital Toxoplasmosis. Eur J Obstet Gynecol Reprod Biol. Sep 1996;68(1-2):93-96. Available at http://www.ncbi.nlm.nih.gov/pubmed/8886688.
- Mitchell CD, Erlich SS, Mastrucci MT, Hutto SC, Parks WP, Scott GB. Congenital toxoplasmosis occurring in infants perinatally infected with human immunodeficiency virus 1. Pediatr Infect Dis J. Jul 1990;9(7):512-518. Available at http://www.ncbi.nlm.nih.gov/pubmed/2371084.
- D'Offizi G, Topino S, Anzidei G, Frigiotti D, Narciso P. Primary Toxoplasma gondii infection in a pregnant human immunodeficiency virus-infected woman. Pediatr Infect Dis J. Oct 2002;21(10):981-982. Available at http://www.ncbi.nlm.nih.gov/pubmed/12400531.
- Vogel N, Kirisits M, Michael E, et al. Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis. Nov 1996;23(5):1055-1060. Available at http://www.ncbi.nlm.nih.gov/pubmed/8922802.
- Centers for Disease Control and Prevention (CDC). HIV/AIDS surveillance report. 1996.
- Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. Jul 19 2006;296(3):292-300. Available at http://www.ncbi.nlm.nih.gov/pubmed/16849662.
- Sobanjo A, Ferguson DJ, Gross U. Primary acquired toxoplasmosis in a five-year-old child with perinatal human immunodeficiency virus type 1 infection. Pediatr Infect Dis J. May 1999;18(5):476-478. Available at http://www.ncbi.nlm.nih.gov/pubmed/10353529.
- Wahn V, Kramer HH, Voit T, Bruster HT, Scrampical B, Scheid A. Horizontal transmission of HIV infection between two siblings. Lancet. Sep 20 1986;2(8508):694. Available at http://www.ncbi.nlm.nih.gov/pubmed/2876170.
- King SM, Matlow A, Al-Hajjar S, al e. Toxoplasmic encephalitis in a child with HIV infection—United States. Pediatr AIDS and HIV Infect. Fetus to Adolesc. 1992;3:242–244.
- McAuley J, Boyer KM, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis. Jan 1994;18(1):38-72. Available at http://www.ncbi.nlm.nih.gov/pubmed/8054436.
- McAuley JB, Boyer KM. Toxoplasmosis. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases 6th Ed. Amsterdam, The Netherlands: Elsevier Press; 2009.
- Medlock MD, Tilleli JT, Pearl GS. Congenital cardiac toxoplasmosis in a newborn with acquired immunodeficiency syndrome. Pediatr Infect Dis J. Feb 1990;9(2):129-132. Available at http://www.ncbi.nlm.nih.gov/pubmed/2314952.
- American Academy of Pediatrics. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. 28th ed. Elk Grove Village, IL2009.
- Pinon JM, Dumon H, Chemla C, et al. Strategy for diagnosis of congenital toxoplasmosis: evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M, and A antibodies. J Clin Microbiol. Jun 2001;39(6):2267-2271. Available at http://www.ncbi.nlm.nih.gov/pubmed/11376068.
- Wilson M, Jones JL, McAuley JB. Toxoplasma. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of clinical microbiology, 9th ed. St. Louis, MO: ASM Press; 2007:2070–2081.
- Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. Jun 12 2004;363(9425):1965-1976. Available at http://www.ncbi.nlm.nih.gov/pubmed/15194258.
- Wong SY, Hajdu MP, Ramirez R, Thulliez P, McLeod R, Remington JS. Role of specific immunoglobulin E in diagnosis of acute toxoplasma infection and toxoplasmosis. J Clin Microbiol. Nov 1993;31(11):2952-2959. Available at http://www.ncbi.nlm.nih.gov/pubmed/8263181.
- McAuley JB, Jones JL, al. e. Toxoplasma. Manual of Clinical Microbiology 10th Ed. Washington, D.C.: American Society of Microbiology Press; 2011.
- Portegies P, Solod L, Cinque P, et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol. May 2004;11(5):297-304. Available at http://www.ncbi.nlm.nih.gov/pubmed/15142222.
- Offiah CE, Turnbull IW. The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol. May 2006;61(5):393-401. Available at http://www.ncbi.nlm.nih.gov/pubmed/16679111.
- US Department of Agriculture. FoodSafety.gov: gateway to government food safety information. 2002. Available at FoodSafety.gov.
- Dubey JP, Kotula AW, Sharar A, Andrews CD, Lindsay DS. Effect of high temperature on infectivity of Toxoplasma gondii tissue cysts in pork. The Journal of parasitology. Apr 1990;76(2):201-204. Available at http://www.ncbi.nlm.nih.gov/pubmed/2319420.
- Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. Jul 15 1992;117(2):106-111. Available at http://www.ncbi.nlm.nih.gov/pubmed/1351371.
- Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. May 15 1995;122(10):755-761. Available at http://www.ncbi.nlm.nih.gov/pubmed/7717598.
- Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. Mar 1995;20(3):531-541. Available at http://www.ncbi.nlm.nih.gov/pubmed/7756472.
- Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. Mar 16 1995;332(11):693-699. Available at http://www.ncbi.nlm.nih.gov/pubmed/7854375.
- Dworkin MS, Hanson DL, Kaplan JE, Jones JL, Ward JW. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis. Aug 2000;182(2):611-615. Available at http://www.ncbi.nlm.nih.gov/pubmed/10915098.
- Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS. Sep 10 1999;13(13):1647-1651. Available at http://www.ncbi.nlm.nih.gov/pubmed/10509565.
- Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet. Jun 24 2000;355(9222):2217-2218. Available at http://www.ncbi.nlm.nih.gov/pubmed/10881897.
- Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis. May 2000;181(5):1635-1642. Available at http://www.ncbi.nlm.nih.gov/pubmed/10823763.
- Miro JM, Lopez JC, Podzamczer D, et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis. Jul 1 2006;43(1):79-89. Available at http://www.ncbi.nlm.nih.gov/pubmed/16758422.
- group Ss, Thiebaut R, Leproust S, Chene G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet. Jan 13 2007;369(9556):115-122. Available at http://www.ncbi.nlm.nih.gov/pubmed/17223474.
- McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. May 15 2006;42(10):1383-1394. Available at http://www.ncbi.nlm.nih.gov/pubmed/16619149.
- Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. Jun 1998;42(6):1346-1349. Available at http://www.ncbi.nlm.nih.gov/pubmed/9624473.
- Beraud G, Pierre-Francois S, Theodose R, et al. Anicteric cholestasis among HIV infected patients with syphilis. Scand J Infect Dis. 2009;41(6-7):524-527. Available at http://www.ncbi.nlm.nih.gov/pubmed/19263273.
- Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. Nov 2005;112(11):1876-1882. Available at http://www.ncbi.nlm.nih.gov/pubmed/16171866.
- Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis. Oct 2007;20(5):482-488. Available at http://www.ncbi.nlm.nih.gov/pubmed/17762781.
- Shah I. Immune Reconstitution Syndrome in HIV-1 infected children - a study from India. Indian J Pediatr. May 2011;78(5):540-543. Available at http://www.ncbi.nlm.nih.gov/pubmed/21203868.
- Caby F, Lemercier D, Coulomb A, et al. Fetal death as a result of placental immune reconstitution inflammatory syndrome. J Infect. Jul 2010;61(2):185-188. Available at http://www.ncbi.nlm.nih.gov/pubmed/20361998.
- Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. Feb 1996;22(2):268-275. Available at http://www.ncbi.nlm.nih.gov/pubmed/8838183.
- Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. Jan 1 1992;116(1):33-43. Available at http://www.ncbi.nlm.nih.gov/pubmed/1727093.
- Duval X, Pajot O, Le Moing V, et al. Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy. AIDS. 2004; 18:1342-4. Available at http://www.ncbi.nlm.nih.gov/pubmed/15362670.
- Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. Mar 10 2000;14(4):383-386. Available at http://www.ncbi.nlm.nih.gov/pubmed/10770540.
- Bertschy S, Opravil M, Cavassini M, et al. Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. Clin Microbiol Infect. Jul 2006;12(7):666-671. Available at http://www.ncbi.nlm.nih.gov/pubmed/16774564.
|Indication||First Choice||Alternative||Comments/Special Issues|
||TMP-SMX 150/750 mg/m2 body surface area once daily by mouth||For Children Aged ≥1 Month:
||Primary Prophylaxis Indicated For:
IgG Antibody to Toxoplasma and Severe Immunosuppression:
Note: Do not discontinue in children aged <1 year
||Secondary Prophylaxis Indicated:
Criteria for Discontinuing Secondary Prophylaxis
If All of the Following Criteria are Fulfilled:
Acute Induction Therapy (Followed by Chronic Suppressive Therapy):
|For Sulfonamide-Intolerant Patients:
|* Note: Sulfadiazine may be given as 2–4 equal doses per day as long as the total daily dose is 85–120 mg/kg body weight.
Key to Acronyms: cART = combination antiretroviral therapy; CBC = complete blood count; CD4 = CD4 T lymphocyte; CNS = central nervous system; CSF = cerebrospinal fluid; IgG = Immunoglobulin G; IM = intramuscular; IV = intravenous; TE = toxoplasmic encephalitis; TMP-SMX = trimethoprim-sulfamethoxazole